These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
176 related articles for article (PubMed ID: 24880663)
41. Treatment of morphea or localized scleroderma: review of the literature. Vilela FA; Carneiro S; Ramos-e-Silva M J Drugs Dermatol; 2010 Oct; 9(10):1213-9. PubMed ID: 20941945 [TBL] [Abstract][Full Text] [Related]
42. Atrophoderma Pasini-Pierini is a primary atrophic abortive morphea. Kencka D; Blaszczyk M; Jabłońska S Dermatology; 1995; 190(3):203-6. PubMed ID: 7599381 [TBL] [Abstract][Full Text] [Related]
43. Early- and late-stage morphea subtypes with deep tissue involvement is treatable with Abatacept (Orencia). Adeeb F; Anjum S; Hodnett P; Kashif A; Brady M; Morrissey S; Devlin J; Fraser AD Semin Arthritis Rheum; 2017 Jun; 46(6):775-781. PubMed ID: 27773434 [TBL] [Abstract][Full Text] [Related]
44. Ultraviolet A1 phototherapy for the treatment of localized scleroderma. Furuhashi T; Torii K; Ikumi K; Kato H; Nishida E; Morita A J Dermatol; 2020 Jul; 47(7):792-795. PubMed ID: 32383187 [TBL] [Abstract][Full Text] [Related]
45. Disabling pansclerotic morphea of childhood--unusual case and management challenges. Forsea AM; Cretu AN; Ionescu R; Giurcaneanu C J Med Life; 2008; 1(3):348-54. PubMed ID: 20108512 [TBL] [Abstract][Full Text] [Related]
46. Localized Scleroderma Cutaneous Assessment Tool (LoSCAT) adapted for use in adult patients: report from an initial validation study. Skrzypek-Salamon A; Lis-Święty A; Ranosz-Janicka I; Brzezińska-Wcisło L Health Qual Life Outcomes; 2018 Sep; 16(1):185. PubMed ID: 30217204 [TBL] [Abstract][Full Text] [Related]
47. Effectiveness of LPG treatment in morphea. Worret WI; Jessberger B J Eur Acad Dermatol Venereol; 2004 Sep; 18(5):527-30. PubMed ID: 15324386 [TBL] [Abstract][Full Text] [Related]
48. "Borrelia-associated early-onset morphea": a particular type of scleroderma in childhood and adolescence with high titer antinuclear antibodies? Results of a cohort analysis and presentation of three cases. Prinz JC; Kutasi Z; Weisenseel P; Pótó L; Battyáni Z; Ruzicka T J Am Acad Dermatol; 2009 Feb; 60(2):248-55. PubMed ID: 19022534 [TBL] [Abstract][Full Text] [Related]
49. Low effectiveness of methotrexate in the management of localised scleroderma (morphea) based on an ultrasound activity score. Vera-Kellet C; Meza-Romero R; Moll-Manzur C; Ramírez-Cornejo C; Wortsman X Eur J Dermatol; 2021 Dec; 31(6):813-821. PubMed ID: 35107072 [TBL] [Abstract][Full Text] [Related]
53. Clinical characteristics associated with antihistone antibodies in patients with localized scleroderma. Sato S; Fujimoto M; Ihn H; Kikuchi K; Takehara K J Am Acad Dermatol; 1994 Oct; 31(4):567-71. PubMed ID: 8089281 [TBL] [Abstract][Full Text] [Related]
54. Localized scleroderma: assessment of the therapeutic response to phototherapy. Buense R; Duarte IA; Bouer M An Bras Dermatol; 2012; 87(1):63-9. PubMed ID: 22481652 [TBL] [Abstract][Full Text] [Related]
55. Clinico-epidemiological Study of Morphea from a Tertiary Care Hospital. Arif T; Adil M; Amin SS; Tahseen M; Dorjay K; Mohtashim M; Singh M; Bansal R; Raj D Curr Rheumatol Rev; 2018; 14(3):251-254. PubMed ID: 29637865 [TBL] [Abstract][Full Text] [Related]
56. Letter: Methotrexate for localized morphea with severe pain: a case report. Jeon H; Kim C Dermatol Online J; 2011 Dec; 17(12):12. PubMed ID: 22233748 [TBL] [Abstract][Full Text] [Related]
57. Usefulness of Dermoscopy in Localized Scleroderma (LoS, Morphea) Diagnosis and Assessment-Monocentric Cross-Sectional Study. Szczepanik-Kułak P; Michalak-Stoma A; Krasowska D J Clin Med; 2022 Jan; 11(3):. PubMed ID: 35160216 [TBL] [Abstract][Full Text] [Related]